RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $113

RBC Capital analyst Leonid Timashev has maintained an 'Outperform' rating on Cytokinetics (NASDAQ: CYTK) and raised the price target from $112 to $113. This adjustment reflects a positive outlook for the company in the market.